论文部分内容阅读
目的:探讨尼洛替尼在伊马替尼不耐受的慢性髓系白血病(CML)患者中的疗效及不良反应。方法:6例伊马替尼耐药的CML患者,其中慢性期5例,进展期1例,持续口服尼洛替尼400mg 2次/d,观察其疗效及不良反应。结果:6例患者平均用药时间为302.5d,5例CML慢性期患者中,3例获得完全细胞遗传学反应,另外2例患者因用药时间分别为15d及25d,故未进行疗效评估;1例急变期患者获得血液学缓解。结论:尼洛替尼对于伊马替尼不耐受的CML患者是有效的,而且耐受性良好,交叉不耐受情况并不常见。
Objective: To investigate the efficacy and adverse reactions of nilotinib in patients with chronic myeloid leukemia (CML) who are intolerant to imatinib. Methods: Six patients with imatinib-resistant CML were enrolled. Among them, 5 were chronic and 1 was advanced. Nilotinib 400 mg twice daily was administered orally to observe its curative effect and side effects. Results: The average duration of medication was 302.5 days in 6 patients, complete cytogenetic response was found in 3 of 5 chronic CML patients, and the other 2 patients were treated for 15d and 25d respectively. Hematological response is achieved in patients with blast crisis. Conclusion: Nilotinib is effective in patients with CML intolerant to imatinib and is well tolerated. Cross-intolerance is not common.